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Abstract
Background: The black-legged (or deer) tick, Ixodes scapularis, commonly infests dogs and cats in North America
and is the main vector for the pathogen that causes Lyme disease in dogs and humans. The speed of kill of a
parasiticide is critical to minimize the direct and deleterious effects of tick infestation and especially to reduce the
risk of tick-borne pathogen transmission. In this study, speed of kill of a novel orally administered isoxazoline
parasiticide, sarolaner chewable tablets (Simparica™), against I. scapularis on dogs was evaluated and compared with
afoxolaner (NexGard®) for five weeks after a single oral dose.
Methods: Twenty four dogs were randomly allocated to treatment with either placebo, sarolaner (2 to 4 mg/kg), or
afoxolaner (2.5 to 6.8 mg/kg) based on pretreatment tick counts. Dogs were examined and live ticks counted at 8,
12, and 24 h after treatment and subsequent re-infestations on Days 7, 14, 21, 28 and 35. Efficacy was determined
at each time point relative to counts for placebo dogs.
Results: A single oral dose of sarolaner provided >99 % efficacy within 24 h of treatment and >95 % against
subsequent weekly re-infestations of ticks consistently to Day 35. For the earlier time points, sarolaner significantly
reduced tick counts versus placebo from Day 0 to Day 21 at 8 and 12 h, and on Day 35 at 12 h (P ≤ 0.0174), while
afoxolaner was only significantly lower at 8 h on Days 0 and 14 (P ≤ 0.0309), and at 12 h on Day 0 only (P < 0.0001).
Significantly more live ticks were recovered from afoxolaner-treated dogs than from sarolaner-treated dogs at 24 h
after infestation from Day 14 to Day 35 (P≤ 0.0278). At 24 h, efficacy (based on geometric mean counts) of afoxolaner
declined to less than 80 % from Day 21 through the end of the study, while efficacy for sarolaner was >95 % for
35 days. There were no adverse reactions to treatments.
Conclusions: In this controlled laboratory evaluation, sarolaner had a faster speed of kill against I. scapularis than
afoxolaner. This was noticeably more pronounced towards the end of the monthly treatment period. The rapid and
consistent kill of ticks provided by sarolaner within 24 h after a single oral dose and re-infestation over 35 days
suggests this treatment will provide highly effective and reliable control of ticks over the entire treatment interval, and
should reduce the risk of tick-borne diseases, including Lyme disease whose agent is vectored by I. scapularis.
Keywords: Ixodes scapularis, Tick, Dog, Sarolaner, Simparica™, Afoxolaner, NexGard®, Isoxazoline, Oral, Speed of kill
* Correspondence: robert.six@zoetis.com
1Zoetis, Veterinary Medicine Research and Development, 333 Portage St.,
Kalamazoo, MI 49007, USA
Full list of author information is available at the end of the article
© 2016 Six et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Six et al. Parasites & Vectors  (2016) 9:79 
DOI 10.1186/s13071-016-1307-x
Background
The black-legged (or deer tick), Ixodes scapularis, is
one of the ticks most commonly infesting dogs and
cats in North America [1]. The tick species is widely
distributed in the northeastern and upper midwestern
United States and southeastern to southcentral
Canada. The occurence and geographic distribution of
I. scapularis ticks is increasing due to the mobility of
people and pets, as well as the increase in wildlife
populations in urban environments. The infestation of
migratory birds also contributes to the geographic ex-
pansion increasing the disease risk for humans, wild-
life, and domestic animals [2, 3].
Ixodes scapularis ticks have become an increasingly
important concern for public and veterinary health [4].
These ticks serve as vectors of Borrelia burgdorferi and
Anaplasma phagocytophilum, the causative agents of
Lyme borreliosis and granulocytic anaplasmosis in
humans and dogs, and may also transmit Babesia
microti. [5, 6]. Ixodes scapularis can also secrete a saliv-
ary neurotoxin that may cause tick paralysis in dogs and
humans [1]. The toxin affects the lower motor neurons
of the spinal cord and cranial nerves and produces a
progressive, ascending flaccid paralysis [7].
Tick control and prevention have taken on a new im-
portance as awareness of and exposure to tick-borne dis-
eases increases and I. scapularis (and other tick species)
populations continue to expand. Until recently, topically
administered parasiticides with contact activity have
been the most common approach to tick control on the
dog. A new class of compounds, the isoxazolines, have
efficacy against fleas and ticks for 1 month or longer fol-
lowing a single oral dose [8, 9]. These systemically active
compounds act rapidly to impact the tick’s feeding be-
havior and cause death of the ticks. Afoxolaner has been
reported to provide >90 % efficacy against Ixodes ricinus
within 24 h for up to 28 days after a single dose [10],
and sarolaner has similarly demonstrated >90 % efficacy
against both I. scapularis and I. ricinus for 28 days [11].
While tick efficacy claims are generally based on evalu-
ation at 48 h after treatment or re-infestation [12], the
speed of acaricidal activity is critical in disrupting or pre-
venting feeding and thus reducing the risk of pathogen
transmission which generally occurs after the infected
tick is attached and feeding for 24 to 48 h [13, 14].
Sarolaner is a novel isoxazoline which in a chewable
tablet formulation (Simparica™) provides excellent con-
trol of fleas and ticks for at least one month after a sin-
gle oral dose (TL McTier, personal communications). A
laboratory study was conducted to evaluate and compare
the speed of kill of sarolaner and afoxolaner (Nexgard®)
against existing I. scapularis infestations and weekly re-
infestations for a period of 5 weeks after treatment with
a single dose.
Methods
The study was a masked, negative-controlled, random-
ized laboratory efficacy design conducted in California,
USA. Study procedures were in accordance with the
World Association for the Advancement of Veterinary
Parasitology (WAAVP) guidelines for evaluating the effi-
cacy of parasiticides for the treatment, prevention and
control of flea and tick infestation on dogs and cats [12]
and complied with the principles of Good Clinical Prac-
tices [15]. The protocol was reviewed and approved by
the local Institutional Animal Care and Use Committee.
Masking of the study was assured through the separ-
ation of functions. All personnel conducting observa-
tions or animal care or performing infestations and
counts were masked to treatment allocation.
Animals
Twenty-four, male and female, purpose-bred Beagles
from 1 to 3 years of age and weighing from 8.1 to
13.8 kg were used in the study. Each dog was individu-
ally identified by a unique ear tattoo or electronic trans-
ponder and had undergone an adequate wash-out period
to ensure that no residual ectoparasiticide efficacy
remained from any previously administered treatments.
Dogs were individually housed in indoor runs such that
no physical contact was possible between them and were
acclimatized to these conditions for at least 14 days prior
to treatment. Dogs were fed an appropriate maintenance
ration of a commercial dry canine feed for the duration
of the study. Water was available ad libitum. All dogs
were given a physical exam to ensure that they were in
good health at enrollment and suitable for inclusion in
the study. General health observations were performed
twice daily throughout the study.
Design
The study followed a randomized complete block design.
Dogs were ranked according to decreasing tick counts
into blocks of three and within each block a dog was
randomly allocated to treatment with placebo, sarolaner,
or afoxolaner. There were eight dogs per treatment
group. Dogs were infested with ticks two days prior to
treatment and then weekly for five weeks. Tick counts
were conducted at 8, 12, and 24 h after treatment and
each subsequent weekly re-infestation.
Treatment
Bodyweights collected on Day −2 were used to deter-
mine the appropriate dose to be administered. On Day
0, dogs received either a placebo tablet, the appropriate
strength sarolaner chewable tablet (Simparica™), to pro-
vide sarolaner at the recommended dose of 2 mg/kg
(range: 2 to 4 mg/kg), or NexGard® per label directions
(afoxolaner at 2.5 to 6.8 mg/kg). All doses were
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administered by hand pilling to ensure accurate and
complete dosing. Each dog was observed for several mi-
nutes after dosing for evidence that the dose was swal-
lowed, and for general health at 1, 4, and 24 h after
treatment administration.
Tick infestation and assessment
The ticks were obtained from the Oklahoma State Uni-
versity’s I. scapularis colony which was initiated in 1991
with engorged females collected locally in Stillwater, OK.
The colony has been maintained with the introduction
of engorged females collected from the local natural
population every two years.
Tick infestations were performed on Days −7 (host
suitability and allocation), −2, 7, 14, 21, 28, and 35. Prior
to each infestation, the dog was lightly sedated with
ketamine/xylazine and a precounted aliquot of 50 (±5)
viable unfed adult I. scapularis were directly applied to
the dog, which was then confined in an appropriately
sized travel crate for 4 h to restrict movement and facili-
tate tick attachment. Each dog was examined to remove
and count live ticks at 48 h after the initial host suitabil-
ity infestation. At 8 and 12 (±0.5) hours after treatment
and each subsequent weekly re-infestation, the dogs
were examined systematically so that the entire body
surface was carefully examined and live ticks were
counted in situ. At 24 h after treatment and each subse-
quent weekly re-infestation, the dogs were examined and
then thoroughly combed to count and remove live ticks.
Each dog was examined for at least 10 min. If ticks were
encountered in the last minute, combing was continued
in 1 min increments until no ticks were encountered.
Statistical analysis
The individual dog was the experimental unit and the
primary endpoint was live tick counts. Data for post-
treatment live (free plus attached) tick counts were sum-
marized with arithmetic (AM) and geometric (GM)
means by treatment group and time point. Tick counts
were transformed by the loge(count + 1) transformation
prior to analysis in order to stabilize the variance and
normalize the data. Using the PROC MIXED procedure
(SAS 9.2, Cary NC), transformed counts were analyzed
using a mixed linear model. The fixed effects were treat-
ment, timepoint and the interaction between timepoint
and treatment by timepoint. The random effects in-
cluded block, block by treatment interaction, and error.
Testing was two-sided at the significance level α = 0.05.
The assessment of efficacy for live ticks was based on
the percent reduction in the AM and GM live tick
counts relative to placebo and to the positive control, as
suggested by the most recent guidelines of the WAAVP
for systemic acaricides [11], and was calculated using
Abbott’s formula:
% reduction ¼ 100  mean count placeboð Þ–mean count treatedð Þ
mean count placeboð Þ
Results
There were no treatment-related adverse events during
the study. Placebo-treated dogs maintained good tick in-
festations throughout the study with mean tick counts
ranging from approximately 20 to 33 (Tables 1, 2 and 3).
At the 8-h timepoint, treatment with sarolaner re-
sulted in significantly lower tick counts than placebo-
treated dogs (P ≤ 0.0174) from treatment through Day
21, and efficacy (GM) ranged from 30.3 to 38.0 % for
this period (Table 1). Treatment with afoxolaner resulted
in significantly lower tick counts than placebo at 8 h on
Days 0 and 14 only (P ≤ 0.0309), with efficacy (GM) of
39.6 and 30.8 %, respectively (Table 1). There were no
significant differences between the mean live tick counts
at 8 h for the sarolaner- and afoxolaner-treated dogs on
any day (P ≥ 0.1028).
At the 12-h timepoint, sarolaner-treated dogs had sig-
nificantly lower tick counts than placebo-treated dogs
(P ≤ 0.0131) from treatment through Day 21, and on Day
35, with efficacy (GM) ranging from 53.3 to 74.9 %
(Table 2). Treatment with afoxolaner resulted in signifi-
cantly lower tick counts than placebo at 12 h on Day 0
only (P < 0.0001), with efficacy (GM) of 68.1 %. Efficacy
for afoxolaner was ≤31.1 % on all other days (Table 2).
Tick counts were significantly higher for afoxolaner-
treated dogs than for sarolaner-treated dogs on Days 7
and 21 (P ≤ 0.0006).
At the 24-h time point, both treatments resulted in
significantly lower tick counts than placebo-treated dogs
(P ≤ 0.0310) throughout the study, and sarolaner-treated
dogs also had significantly fewer ticks than afoxolaner-
treated dogs (P ≤ 0.0278) on Days 14, 21, 28, and 35
(Table 3). Treatment with sarolaner resulted in efficacy
(GM) of at least 95.7 % through Day 35, while efficacy
for dogs treated with afoxolaner declined below 80 %
from Day 21 onwards (Table 3, Fig. 1).
Discussion
A single dose of sarolaner resulted in the rapid re-
duction of an existing infestation with I. scapularis
ticks and the rapid kill of re-infestations for 5 weeks
after treatment. Efficacy of >90 % was achieved within
24 h for 28 days. Rapid kill of ticks is key to amelior-
ating the direct adverse effects of tick feeding and is
critical in reducing the risk of transmission of tick-
borne pathogens. Transmission of B. burgforferi is
considered not to occur until ticks have been at-
tached for at least 48 h [16, 17], and transmission
rates of B. burgdorferi and A. phagocytophilum have
been shown to drop significantly if ticks are
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Table 1 Mean live Ixodes scapularis counts and efficacy relative to placebo at 8 h after treatment and post-treatment re-infestations
for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0
Treatment Day of treatment or re-infestation
0 7 14 21 28 35
Placebo Range 20–40 12–32 17–37 18–40 12–32 15–34
A. mean 30.3 25.5 25.4 28.6 24.1 23.8
G. mean1 29.4a 24.2a 24.5a 27.8a 23.2a 23.0a
Sarolaner Range 15–25 11–24 10–30 13–36 16–35 13–36
A. mean 20.8 16.8 16.1 19.6 25.6 23.1
Efficacy (%) 31.4 34.3 36.5 31.4 0.0 2.6
G. mean1 20.5b 16.2b 15.2b 18.5b 25.0a 21.9a
Efficacy (%) 30.3 32.8 38.0 33.5 0.0 5.0
P-value vs. placebo 0.0082 0.0174 0.0070 0.0065 0.5822 0.6940
Afoxolaner Range 12–27 12–27 11–26 17–36 15–34 17–25
A. mean 18.4 21.8 17.6 23.3 23.6 20.0
Efficacy (%) 39.3 14.7 30.5 18.8 2.1 15.8
G. mean1 17.8b 21.1a,b 17.0b 22.7a,b 22.7a 19.9a
Efficacy (%) 39.6 12.5 30.8 18.5 1.9 13.8
P-value vs. placebo 0.0006 0.3909 0.0309 0.1445 0.8889 0.2619
P-value vs. sarolaner 0.2569 0.1028 0.5023 0.1487 0.4914 0.4585
1Geometric means within columns with the same superscript are not significantly different (P > 0.05)
Table 2 Mean live Ixodes scapularis counts and efficacy relative to placebo at 12 h after treatment and post-treatment re-infestations
for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0
Treatment Day of treatment or re-infestation
0 7 14 21 28 35
Placebo Range 20–43 13–30 10–39 15–36 15–36 18–33
A. mean 32.9 23.1 24.4 26.3 23.9 25.4
G. mean1 32.0a 22.3a 22.6a 25.4a 23.1a 24.7a
Sarolaner Range 4–22 6–14 0–18 1–26 12–35 1–29
A. mean 9.1 9.5 12.1 10.3 18.6 15.4
Efficacy (%) 72.2 58.9 50.3 61.0 22.0 39.4
G. mean1 8.0b 9.1b 9.5b 7.9b 17.5a 11.6b
Efficacy (%) 74.9 59.2 58.0 68.8 24.0 53.3
P-value vs. placebo <0.0001 <0.0001 0.0120 0.0002 0.1054 0.0131
Afoxolaner Range 5–15 11–29 12–21 12–40 11–38 14–23
A. mean 10.6 18.5 15.9 23.6 21.5 19.3
Efficacy (%) 67.7 20.0 34.9 10.0 9.9 24.1
G. mean1 10.2b 17.6a 15.6a,b 22.3a 20.1a,b 19.0a,b
Efficacy (%) 68.1 21.2 31.1 12.0 13.0 23.3
P-value vs. placebo <0.0001 0.1335 0.2460 0.6168 0.4013 0.3512
P-value vs. sarolaner 0.3063 0.0004 0.1369 0.0006 0.4123 0.0949
1Geometric means within columns with the same superscript are not significantly different (P > 0.05)
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prevented from feeding for more than 24 h [18].
Thus, the rapid efficacy of a single oral dose of saro-
laner demonstrated here that resulted in the kill of
the majority of ticks within 24 h of weekly re-
infestations for 1 month should provide a marked
reduction in the risk of a treated dog becoming in-
fected with the pathogens transmitted by I. scapularis.
Efficacy of afoxolaner against I. scapularis has been
described previously with assessment at 48 h after treat-
ment and weekly re-infestations; Mitchell et al. [19]
Table 3 Mean live Ixodes scapularis counts and efficacy relative to placebo at 24 h after treatment and post-treatment re-infestations
for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0
Treatment Day of treatment or re-infestation
0 7 14 21 28 35
Placebo Range 26–39 3–32 12–32 4–36 16–32 14–29
A. mean 32.4 23.9 23.4 27.5 23.5 22.9
G. mean1 32.0a 20.5a 22.4a 23.9a 23.1a 22.4a
Sarolaner Range 0–1 0–1 0–0 0–3 0–5 0–17
A. mean 0.1 0.3 0.0 0.5 1.3 2.6
Efficacy (%) 99.6 99.0 100 98.2 94.7 88.5
G. mean1 0.1b 0.2b 0.0c 0.3c 0.8c 1.0c
Efficacy (%) 99.7 99.1 100 98.8 96.6 95.7
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Afoxolaner Range 0–2 0–6 0–9 1–15 1–21 0–25
A. mean 0.3 1.8 2.4 6.9 9.0 12.1
Efficacy (%) 99.2 92.7 89.8 75.0 61.7 47.0
G. mean1 0.1b 1.0b 1.1b 5.3b 6.5b 6.8b
Efficacy (%) 99.5 95.1 95.1 77.9 71.8 69.6
P-value vs. placebo <0.0001 <0.0001 <0.0001 0.0003 0.0009 0.0310
P-value vs. sarolaner 0.7558 0.1197 0.0278 <0.0001 0.0001 0.0083
1Geometric means within columns with the same superscript are not significantly different (P > 0.05)
Fig. 1 Percent efficacy based on geometric mean counts relative to placebo at 12 and 24 h after treatment and weekly post-treatment
re-infestations of Ixodes scapularis for dogs treated with a single oral dose of sarolaner or afoxolaner on Day 0
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reported efficacy (GM) of 98.4 % against an existing in-
festation and ≥94.2 % against re-infestations up to Day
28. This level of efficacy for afoxolaner at 48 h is similar
to the efficacy achieved by sarolaner at 24 h in this
study, and further highlights the speed of tick kill follow-
ing a single dose of sarolaner. Also notable was the
consistency of sarolaner’s efficacy at 24 h after re-
infestations over the duration of the treatment interval,
while efficacy of afoxolaner at 24 h declined significantly
to less than 80 % from Day 21 onwards. This consistent
and rapid kill of ticks within 24 h over a full month fol-
lowing a single administration of sarolaner supports the
potential for the product to aid in the prevention of the
transmission of tick-borne pathogens to dogs.
Conclusions
This study confirmed the excellent acaricidal efficacy of
sarolaner against I. scapularis after a single oral adminis-
tration. Ticks were killed rapidly, with the majority of
ticks killed within 24 h after weekly re-infestations for
5 weeks. Efficacy for sarolaner-treated dogs was consist-
ently higher than that of afoxolaner from Day 14 on-
wards at 24 h. Thus, sarolaner chewable tablets
(Simparica™) offers the pet owner and the veterinarian
an efficacious oral product with a rapid speed of kill of
ticks over the entire month following a single oral dose,
and will be an important new tool in the treatment and
prevention of tick infestation, and should reduce the risk
of tick–borne pathogen transmission.
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